Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hanna M et al. – The results of this extension study suggest that long–term repeated dosing with once–daily OROSĀ® hydromorphone can be beneficial in the continuing management of persistent, moderate–to–severe cancer pain.

Related Articles

The Role of OROS Hydromorphone in the Management of Cancer Pain
Pain Practice, 10/27/09    Relevance Score: 82%

Core Aspects of Satisfaction with Pain Management: Cancer Patients' Perspectives
Journal of Pain and Symptom Management, 11/02/09    Relevance Score: 68%

Outpatient Continuous Interscalene Brachial Plexus Block in Cancer-Related Pain
Journal of Pain and Symptom Management, 11/03/09    Relevance Score: 67%

Global perspectives on cancer pain
Pain Research and Management, 10/27/09    Relevance Score: 67%

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial
Current Medical Research and Opinion, 10/08/09    Relevance Score: 67%

Today in Pain Management/Palliative Care...keeping you current

End-of-Life Issues in Critically Ill Cancer Patients
Critical Care Clinics, 12/03/09

Childhood abuse uncovered in a palliative care audit
Palliative & Supportive Care, 12/03/09

Activity and meaning making in the everyday lives of people with advanced cancer
Palliative & Supportive Care, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address